Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Acarix ABACIXF -0.01%39 Earnings per Share (Diluted) is $-0.00 as of Mar. 2026. GuruFocus rates ACIXF with a GF Score™ of 39/100 and a GF Value™ of $0.02 (Modestly Overvalued). The stock has 1 warning sign investors should review. Among 661 Medical Devices & Instruments companies, Acarix AB ranks better than 88.5% on this metric.
Acarix AB's EPS (Basic) for the
three
months ended in Mar. 2026 was $-0.00.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 was $-0.00.
Acarix AB's EPS without NRI for the
three
months ended in Mar. 2026 was $-0.00.
Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 was $-0.00.
During the past 3 years, the average EPS without NRIGrowth Rate was 49.50% per year.
During the past 5 years, the average EPS without NRIGrowth Rate was 38.70% per year.
During the past 10 years, the average EPS without NRIGrowth Rate was 26.30% per year.
During the past 12 years, Acarix AB's highest 3-Year average EPS without NRI Growth Rate was 49.50% per year. The lowest was -33.50% per year. And the median was 27.60% per year.
Acarix AB (OTCPK:ACIXF) Earnings per Share (Diluted) Explanation
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Acarix AB Earnings per Share (Diluted) Related Terms
Acarix AB Earnings per Share (Diluted) Historical Data
* Premium members only.
The historical data trend for Acarix AB's Earnings per Share (Diluted) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ACIXF vs ABT, SYK, MDT: Earnings per Share (Diluted) Comparison
For the Medical Devices subindustry, Acarix AB's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Acarix AB PE Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Acarix AB's PE Ratio distribution charts can be found below:
* The bar in red indicates where Acarix AB's PE Ratio falls into.
Acarix AB Earnings per Share (Diluted) Calculation
Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.
Acarix AB's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2025 is calculated as
Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.00
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.
What does a Earnings per Share (Diluted) of $-0.00 mean?
Acarix AB (ACIXF) has a Earnings per Share (Diluted) of $-0.00 as of Mar. 2026. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on Acarix AB and its competitors. According to the industry distribution chart, Acarix AB ranks #76 out of 661 companies in the Medical Devices & Instruments industry, placing it in the top 11.5%.
Is Acarix AB's Earnings per Share (Diluted) too high?
Acarix AB's current Earnings per Share (Diluted) is $-0.00. Based on the distribution chart, Acarix AB ranks #76 out of 661 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Acarix AB has a GF Score™ of 39/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Acarix AB's Earnings per Share (Diluted) compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Acarix AB ranks #76 out of 661 companies for Earnings per Share (Diluted). This places Acarix AB in the top 12% of its industry — outperforming the majority of peers. The industry median Earnings per Share (Diluted) is 8.20. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings per Share (Diluted) for a Medical Devices & Instruments company?
The median Earnings per Share (Diluted) among Medical Devices & Instruments companies is 8.20, based on 661 companies in the industry. Companies in the top quartile (top 25%) have a Earnings per Share (Diluted) significantly above this median, while those in the bottom quartile fall well below. However, Earnings per Share (Diluted) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings per Share (Diluted) mean?
A high Earnings per Share (Diluted) can signal that a stock is expensive relative to its fundamentals. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on Acarix AB and its competitors. For the Medical Devices & Instruments industry, the median Earnings per Share (Diluted) is 8.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Acarix AB's current Earnings per Share (Diluted) is $-0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Acarix AB stock overvalued right now?
Based on GuruFocus' analysis, Acarix AB (ACIXF) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.02, compared to a current price of $0.03 — trading 30.3% above its estimated fair value. The current Earnings per Share (Diluted) is $-0.00. Acarix AB's overall GF Score™ is 39/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings per Share (Diluted) calculated?
Earnings per Share (Diluted) is calculated from a company's financial statements. For Acarix AB (ACIXF), the current Earnings per Share (Diluted) is $-0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Acarix AB (ACIXF) Overvalued in 2026?
Based on GuruFocus' analysis, Acarix AB stock appears to be overvalued.
The current stock price of $0.03 is trading 30.3% above its estimated GF Value™ of $0.02.
GuruFocus considers Acarix AB to be Modestly Overvalued.
Key valuation signals for ACIXF:
Earnings per Share (Diluted): $-0.00
GF Value™: $0.02 vs. price of $0.03 (30.3% above fair value)
No single metric tells the full story. See the ACIXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Acarix AB is a Swedish medical technology company that develops solutions for rapid AI-based exclusion of coronary artery disease (CAD). Its CE-marked CADScor System, which has also received DeNovo approval from the FDA, is intended for patients experiencing chest pain with suspected coronary artery disease and is designed to help reduce millions of cases of unnecessary, invasive, and costly diagnostics. Acarix recommends the CADScor System as a first-line diagnostic tool that uses sensitive acoustics and computational processing to analyze coronary blood flow to rule out coronary artery disease (CAD), with a majority certainty at the point of care. Geographically, the company generates maximum revenue from the United States, and the rest from Germany, Sweden, Iraq, and other regions.
39GF Score
Get the complete analysis for ACIXF
Earnings per Share (Diluted) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ACIXF has been successfully added to your 
